Monitor Resmed's upcoming quarterly reports for any contribution from Noctrix's Nidra therapy and management commentary on RLS market penetration. The acquisition strengthens Resmed's sleep health offering beyond sleep apnea, but financial impact is likely modest in the near term.
Price Chart
Executive Summary
Resmed completed its acquisition of Noctrix Health, adding an FDA-cleared non-pharmacologic treatment for Restless Legs Syndrome (RLS) to its sleep health portfolio. The deal size was not disclosed, but the acquisition aligns with Resmed's 2030 strategy and expands its clinical sleep health offering beyond sleep apnea into RLS, the third most prevalent sleep disorder.
Key Facts
- Resmed completed acquisition of Noctrix Health on June 1, 2026.
- Noctrix's Nidra TOMAC Therapy is an FDA De Novo classified non-invasive treatment for moderate-to-severe RLS.
- The therapy is included in AASM clinical practice guidelines and supported by 10 peer-reviewed publications.
- Noctrix becomes a wholly owned subsidiary of Resmed.
- Financial terms of the acquisition were not disclosed.
Financial Impact
Not disclosed; strategic acquisition expected to expand portfolio into adjacent RLS market.
Risk Factors
- Integration and commercial execution of Noctrix's therapy into Resmed's portfolio.
- RLS treatment market adoption and reimbursement uncertainties.
- Potential for lower-than-expected revenue contribution from the newly acquired asset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304704 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Insider Cluster | $219.58 $228.42 | ▲ +4.03% | ▲ +4.52% | $218.89 (−0.31%) |
Aug 11, 2026 7w ago | Insider Cluster | $224.84 $219.98 | ▼ −2.16% | ▼ −1.76% | $218.89 (−2.65%) |
Jul 7, 2026 12w ago | Press Release | $205.84 $193.01 | ▼ −6.23% | ▼ −7.10% | $218.89 (+6.34%) |
Jun 1, 2026 17w ago | Press Release | $182.75 $196.94 | ▲ +7.77% | ▲ +10.73% | $218.89 (+19.78%) |
May 19, 2026 19w ago | Press Release | $209.14 $203.22 | ▲ +2.83% | ▲ +4.63% | $218.89 (−4.66%) |
Apr 1, 2026 26w ago | Press Release | $224.09 $228.07 | ▲ +1.78% | ▼ −1.84% | $218.89 (−2.32%) |
Apr 1, 2026 26w ago | Insider Cluster | $222.19 $228.02 | ▲ +2.62% | ▼ −1.14% | $218.89 (−1.48%) |
Apr 1, 2026 26w ago | Insider Cluster | $222.19 $228.02 | ▼ −2.62% | ▲ +1.14% | $218.89 (+1.48%) |
Mar 2, 2026 30w ago | Insider Cluster | $256.94 $252.06 | ▼ −1.90% | ▼ −0.69% | $218.89 (−14.81%) |
Mar 2, 2026 30w ago | Insider Cluster | $256.94 $252.06 | ▼ −1.90% | ▼ −0.69% | $218.89 (−14.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access